<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">lvrach</journal-id><journal-title-group><journal-title xml:lang="ru">Лечащий Врач</journal-title><trans-title-group xml:lang="en"><trans-title>Lechaschi Vrach</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1560-5175</issn><issn pub-type="epub">2687-1181</issn><publisher><publisher-name></publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.51793/OS.2025.28.6.012</article-id><article-id custom-type="elpub" pub-id-type="custom">lvrach-1436</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>АКТУАЛЬНАЯ ТЕМА. ОСТЕОПОРОЗ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>TOPICAL THEME. OSTEOPOROSIS</subject></subj-group></article-categories><title-group><article-title>Особенности применения антибактериального препарата джозамицин в гинекологической практике</article-title><trans-title-group xml:lang="en"><trans-title>Features of the use of the antibacterial drug josamycin in gynecological practice</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-7591-6281</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Хашукоева</surname><given-names>А. З.</given-names></name><name name-style="western" xml:lang="en"><surname>Khashukoeva</surname><given-names>A. Z.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Хашукоева Асият Зульчифовна, д.м.н., профессор кафедры акушерства и гинекологии Института хирургии</p><p>117513, Москва, ул. Островитянова, 1</p></bio><bio xml:lang="en"><p>Asiyat Z. Khashukoeva, Dr. of Sci. (Med.), Professor of the Department of Obstetrics and Gynecology, Faculty of Medicine</p><p>1 Ostrovityanova str., Moscow, 117513</p></bio><email xlink:type="simple">azk@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-5138-8357</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Агаева</surname><given-names>М. И.</given-names></name><name name-style="western" xml:lang="en"><surname>Agaeva</surname><given-names>M. I.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Агаева Мадина Ильясовна, к.м.н., ассистент кафедры акушерства и гинекологии Института хирургии</p><p>117513, Москва, ул. Островитянова, 1</p></bio><bio xml:lang="en"><p>Madina I. Agaeva, Cand. of Sci. (Med.), Assistant of the Department of Obstetrics and Gynecology, Faculty of Medicine</p><p>1 Ostrovityanova str., Moscow, 117513</p></bio><email xlink:type="simple">madlen1690@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-2205-0880</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Агаева</surname><given-names>З. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Agaeva</surname><given-names>Z. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Агаева Зоя Абуевна, д.м.н., профессор, старший преподаватель отдела ультразвуковых и функциональных методов исследований</p><p>107045, Москва, Большая Сухаревская площадь, 3, стр. 21</p></bio><bio xml:lang="en"><p>Zoya A. Agaeva, Dr. of Sci. (Med.), Professor, Senior Lecturer in the Department of Ultrasound and Functional Research Methods</p><p>3, b. 21 Bolshaya Sukharevskaya Square, Moscow, 107045</p></bio><email xlink:type="simple">zoya466@mail.ru</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-0304-4901</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Бурденко</surname><given-names>М. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Burdenko</surname><given-names>M. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Бурденко Марина Владимирована, к.м.н., доцент кафедры акушерства и гинекологии Института хирургии</p><p>117513, Москва, ул. Островитянова, 1</p></bio><bio xml:lang="en"><p>Marina V. Burdenko, Cand. of Sci. (Med.), Associate Professor of the Department of Obstetrics and Gynecology, Faculty of Medicine</p><p>1 Ostrovityanova str., Moscow, 117513</p></bio><email xlink:type="simple">bmv-0306@rambler.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-0925-3755</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Носова</surname><given-names>Л. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Nosova</surname><given-names>L. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Носова Лилия Андреевна, ассистент кафедры акушерства и гинекологии Института хирургии</p><p>117513, Москва, ул. Островитянова, 1</p></bio><bio xml:lang="en"><p>Liliya A. Nosova, assistant of the Department of Obstetrics and Gynecology, Faculty of Medicine</p><p>1 Ostrovityanova str., Moscow, 117513</p></bio><email xlink:type="simple">karelina_lilia0@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0000-4378-910X</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Хашукоева</surname><given-names>И. З.</given-names></name><name name-style="western" xml:lang="en"><surname>Khashukoeva</surname><given-names>I. Z.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Хашукоева Илона Заурбиевна, студентка Медицинской академии</p><p>360004, Нальчик, ул. Чернышевского, 173</p></bio><bio xml:lang="en"><p>Ilona Z. Khashukoeva, student of Medical Academy</p><p>173 Chernyshevsky str., Nalchik, 360004</p></bio><email xlink:type="simple">ilona_1017@mail.ru</email><xref ref-type="aff" rid="aff-3"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Российский национальный исследовательский медицинский университет имени Н. И. Пирогова</institution><country>Россия</country></aff><aff xml:lang="en"><institution>N. I. Pirogov Russian National Research Medical University</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>Научно-исследовательский институт скорой помощи им. Н. В. Склифосовского Департамента здравоохранения города Москвы</institution><country>Россия</country></aff><aff xml:lang="en"><institution>N. V. Sklifosovsky Scientific Research Institute of Emergency Medicine of the Moscow City Health Department</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-3"><aff xml:lang="ru"><institution>Кабардино-Балкарский государственный университет имени Х. М. Бербекова</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Kabardino-Balkarian State University named after Kh. M. Berbekov</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2025</year></pub-date><pub-date pub-type="epub"><day>12</day><month>06</month><year>2025</year></pub-date><volume>0</volume><issue>6</issue><fpage>82</fpage><lpage>86</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Хашукоева А.З., Агаева М.И., Агаева З.А., Бурденко М.В., Носова Л.А., Хашукоева И.З., 2025</copyright-statement><copyright-year>2025</copyright-year><copyright-holder xml:lang="ru">Хашукоева А.З., Агаева М.И., Агаева З.А., Бурденко М.В., Носова Л.А., Хашукоева И.З.</copyright-holder><copyright-holder xml:lang="en">Khashukoeva A.Z., Agaeva M.I., Agaeva Z.A., Burdenko M.V., Nosova L.A., Khashukoeva I.Z.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://journal.lvrach.ru/jour/article/view/1436">https://journal.lvrach.ru/jour/article/view/1436</self-uri><abstract><sec><title>Введение</title><p>Введение. В настоящее время первое место по распространенности среди всех бактериальных заболеваний, передающихся половым путем, занимает урогенитальный хламидиоз. Наряду с хламидиями в этиологии урогенитальных заболеваний все большее внимание привлекают другие внутриклеточные возбудители – микоплазмы и уреаплазмы. Воспалительные заболевания органов малого таза наносят существенный урон здоровью женщины, способствуют нарушению репродуктивной функции, снижению качества жизни, а также формированию угрожающих жизни состояний при тяжелом течении. Вопросы своевременной диагностики воспалительных заболеваний органов репродуктивной системы представляют множество сложностей, связанных со стертостью клинической симптоматики, многообразием возбудителей, а также различным течением воспалительного процесса. Neisseria gonorrhoeae, Chlamydia trachomatis, Mycoplasma genitalium, Trichomonas vaginalis являются ведущими этиологическими факторами воспалительных заболеваний органов малого таза, до 60% случаев воспалительных заболеваний женских половых органов являются следствием микробных ассоциаций Chlamydia trachomatis и Mycoplasma genitalium. Наибольшую опасность данные инфекции представляют во время беременности. Сложности диагностики приводят к запоздалому лечению, что способствует увеличению числа хронических форм заболеваний и неблагоприятных исходов, связанных с осложненным течением болезней. Терапия воспалительных заболеваний половых органов требует комплексного подхода и вызывает множество дискуссий, основным звеном лечения является рациональный подбор антибактериальной терапии.</p></sec><sec><title>Результаты</title><p>Результаты. В настоящем обзоре продемонстрированы современные данные о высокой эффективности и безопасности применения джозамицина в терапии данных нозологий. Применение отечественного препарата с действующим веществом джозамицин в терапии воспалительных заболеваний органов малого таза, урогенитального хламидиоза и микоплазмоза, в особенности в период беременности, является эффективным и безопасным, позволит сократить частоту неблагоприятных исходов беременности и инфекционно-воспалительных осложнений.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Background</title><p>Background. Currently, urogenital chlamydia occupies the first place in terms of prevalence among all bacterial sexually transmitted diseases. Along with chlamydia, other intracellular pathogens, mycoplasmas and ureaplasmas, are attracting increasing attention in the etiology of urogenital diseases. Inflammatory diseases of the pelvic organs cause significant damage to the health of women, contribute to the violation of reproductive function, reduce the quality of life, as well as the formation of life-threatening conditions in severe course. The issues of timely diagnosis of inflammatory diseases of the reproductive system present many difficulties, justified by the vagueness of clinical symptoms, the variety of causative agents, as well as the different course of the inflammatory process. Neisseria gonorrhoeae, Chlamydia trachomatis, Mycoplasma genitalium, Trichomonas vaginalis are the leading etiologic factors of inflammatory diseases of pelvic organs, up to 60% of cases of inflammatory diseases of female genital organs are the result of microbial associations of Chlamydia trachomatis, Mycoplasma genitalium. These infections are most dangerous during pregnancy. Difficulties in diagnosis lead to delayed treatment, which contributes to an increase in the number of chronic forms of diseases and unfavorable outcomes associated with a complicated course of diseases. Therapy of inflammatory diseases of the genitals requires a comprehensive approach and causes a lot of discussion, the main link of treatment is the rational selection of antibacterial therapy.</p></sec><sec><title>Results</title><p>Results. This review demonstrates current data on the high efficacy and safety of the use of josamycin in the treatment of these diseases. The use of the domestic drug with active substance josamycin in the treatment of inflammatory diseases of the pelvic organs, urogenital chlamydia and mycoplasmosis, especially during pregnancy, is effective and safe, and will reduce the frequency of adverse pregnancy outcomes and infectious and inflammatory complications.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>джозамицин</kwd><kwd>хламидии</kwd><kwd>микоплазмы</kwd><kwd>беременность</kwd></kwd-group><kwd-group xml:lang="en"><kwd>josamycin</kwd><kwd>chlamydia</kwd><kwd>mycoplasma</kwd><kwd>pregnancy</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Хашукоева А. З., Агаева М. И., Агаева З. А., СавченкоТ. Н., Лобпчева Ю. И. Воспалительные заболевания органов малого таза: современные алгоритмы диагностики и лечения. Лечащий Врач. 2024; 5 (27): 12-17.</mixed-citation><mixed-citation xml:lang="en">Khashukoeva A. Z., Agaeva M. I., Agaeva Z. A., Savchenko T. N., Lobpcheva Yu. I. Inflammatory diseases of pelvic organs: modern algorithms of diagnosis and treatment. Lechaschi Vrach. 2024. 27 (5): 12-17. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Damkier P., Brønniche L. M. S., Korch-Frandsen J. F. B., Broe A. In utero exposure to antibiotics and risk of congenital malformations: a population-based study. Am J Obstet Gynecol. 2019; 221 (6): 648.e1-648.e15. DOI: 10.1016/j.ajog.2019.06.050. PubMed.</mixed-citation><mixed-citation xml:lang="en">Damkier P., Brønniche L. M. S., Korch-Frandsen J. F. B., Broe A. In utero exposure to antibiotics and risk of congenital malformations: a population-based study. Am J Obstet Gynecol. 2019; 221 (6): 648.e1-648.e15. DOI: 10.1016/j.ajog.2019.06.050. PubMed.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Tubiana S., Sibiude J., Herlemont P., Drouin J., Picone O., Duval X., et al. Trends in anti-infective use during pregnancy in France between 2010 and 2019: a nationwide population-based study. Br J Clin Pharmacol. 2023; 89 (5): 1629-1639. DOI: 10.1111/bcp.15638. PubMed.</mixed-citation><mixed-citation xml:lang="en">Tubiana S., Sibiude J., Herlemont P., Drouin J., Picone O., Duval X., et al. Trends in anti-infective use during pregnancy in France between 2010 and 2019: a nationwide population-based study. Br J Clin Pharmacol. 2023; 89 (5): 1629-1639. DOI: 10.1111/bcp.15638. PubMed.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Ушкалова Е. А. Место джозамицина в лечении урогенитальных инфекций, вызываемых внутриклеточными возбудителями. Фарматека. 2006; 4 (119): 5-6.</mixed-citation><mixed-citation xml:lang="en">Ushkalova E. A. The place of josamycin in the treatment of urogenital infections caused by intracellular pathogens. Farmateka. 2006. 4 (119): 5-6. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Mansour O., Russo R. G., Straub L., Bateman B. T., Gray K. J., Huybrechts K. F., et al. Prescription medication use during pregnancy in the United States from 2011 to 2020: trends and safety evidence. Am J Obstet Gynecol. 2024; 231 (2): 250.e1–250.e16. DOI: 10.1016/j.ajog.2023.12.020. PMC – PubMed.</mixed-citation><mixed-citation xml:lang="en">Mansour O., Russo R. G., Straub L., Bateman B. T., Gray K. J., Huybrechts K. F., et al. Prescription medication use during pregnancy in the United States from 2011 to 2020: trends and safety evidence. Am J Obstet Gynecol. 2024; 231 (2): 250.e1–250.e16. DOI: 10.1016/j.ajog.2023.12.020. PMC – PubMed.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Bookstaver P. B., Bland C. M., Griffin B., Stover K. R., Eiland L. S., McLaughlin M. A. Review of Antibiotic Use in Pregnancy. Pharmacotherapy. 2015. Р. 1052-1062. Available from: https://www.ncbi.nlm.nih.gov/pubmed/26598097. PubMed.</mixed-citation><mixed-citation xml:lang="en">Bookstaver P. B., Bland C. M., Griffin B., Stover K. R., Eiland L. S., McLaughlin M. A. Review of Antibiotic Use in Pregnancy. Pharmacotherapy. 2015. Р. 1052-1062. Available from: https://www.ncbi.nlm.nih.gov/pubmed/26598097. PubMed.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Лоран О. Б., Синякова Л. А., Косова И. В. Неосложненные инфекции мочевыводящих путей: проблема выбора рациональной антимикробной терапии. Фарматека. 2004; 11.</mixed-citation><mixed-citation xml:lang="en">Loran O. B., Sinyakova L. A., Kosova I. V. Uncomplicated urinary tract infections: the problem of choosing a rational antimicrobial therapy. Farmateka. 2004. № 11. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Antonucci R., Cuzzolin L., Locci C., Dessole F., Capobianco G. Use of azithromycin in pregnancy: more doubts than Certainties. Clin Drug Investig. 2022; 42 (11): 921-935. DOI: 10.1007/s40261-022-01203-0. PMC – PubMed.</mixed-citation><mixed-citation xml:lang="en">Antonucci R., Cuzzolin L., Locci C., Dessole F., Capobianco G. Use of azithromycin in pregnancy: more doubts than Certainties. Clin Drug Investig. 2022; 42 (11): 921-935. DOI: 10.1007/s40261-022-01203-0. PMC – PubMed.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Zimmerman M. S., Smith A. G. C., Sable C. A., Echko M. M., Wilner L. B., Olsen H. E., et al. Global, regional, and national burden of congenital heart disease, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Child Adolesc Health. 2020; 4 (3): 185-200. DOI: 10.1016/S23524642(19)30402-X. PMC – PubMed.</mixed-citation><mixed-citation xml:lang="en">Zimmerman M. S., Smith A. G. C., Sable C. A., Echko M. M., Wilner L. B., Olsen H. E., et al. Global, regional, and national burden of congenital heart disease, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Child Adolesc Health. 2020; 4 (3): 185-200. DOI: 10.1016/S23524642(19)30402-X. PMC – PubMed.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Майоров М. В. Урогенитальный хламидиоз в амбулаторной гинекологии. Провизор. 2004; 10.</mixed-citation><mixed-citation xml:lang="en">Майоров М. В. Урогенитальный хламидиоз в амбулаторной гинекологии. Провизор. 2004; 10. Mayorov M. V. Urogenital chlamydia in outpatient gynecology. Provizor. 2004; 10. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Fan H., Gilbert R., O’Callaghan F., Li L. Associations between macrolide antibiotics prescribing during pregnancy and adverse child outcomes in the UK: population based cohort study. BMJ. 2020; 368: m331. DOI: 10.1136/bmj.m331. PMC – PubMed.</mixed-citation><mixed-citation xml:lang="en">Fan H., Gilbert R., O’Callaghan F., Li L. Associations between macrolide antibiotics prescribing during pregnancy and adverse child outcomes in the UK: population based cohort study. BMJ. 2020; 368: m331. DOI: 10.1136/bmj.m331. PMC – PubMed.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Andersson N. W., Olsen R. H., Andersen J. T. Association between use of macrolides in pregnancy and risk of major birth defects: nationwide, register based cohort study. BMJ. 2021; 372: n107. DOI: 10.1136/bmj.n107. PMC – PubMed.</mixed-citation><mixed-citation xml:lang="en">Andersson N. W., Olsen R. H., Andersen J. T. Association between use of macrolides in pregnancy and risk of major birth defects: nationwide, register based cohort study. BMJ. 2021; 372: n107. DOI: 10.1136/bmj.n107. PMC – PubMed.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Muanda F., Sheehy O., Bérard A. Use of antibiotics during pregnancy and the risk of major congenital malformations: a population based cohort study. Br J ClinPharmacol. 2017; 83 (12): 2557-2571. PMC – PubMed.</mixed-citation><mixed-citation xml:lang="en">Muanda F., Sheehy O., Bérard A. Use of antibiotics during pregnancy and the risk of major congenital malformations: a population based cohort study. Br J ClinPharmacol. 2017; 83 (12): 2557-2571. PMC – PubMed.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Bérard A., Sheehy O., Zhao J.-P., Nordeng H. Use of macrolides during pregnancy and the risk of birth defects: a population-based study. Pharmacoepidemiol Drug Saf. 2015; 24 (12): 1241-1248. DOI: 10.1002/pds.3900. PubMed.</mixed-citation><mixed-citation xml:lang="en">Bérard A., Sheehy O., Zhao J.-P., Nordeng H. Use of macrolides during pregnancy and the risk of birth defects: a population-based study. Pharmacoepidemiol Drug Saf. 2015; 24 (12): 1241-1248. DOI: 10.1002/pds.3900. PubMed.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Тютюнник В. Л., Михайлова О. И., Меджидова М. К. Неспецифический вагинит: этиология, патогенез, клиника, диагностика, современные принципы лечения. Акушерство и гинекология. 2011; 7-2: 92-96.</mixed-citation><mixed-citation xml:lang="en">Tyutyunnik V. L., Mikhailova O. I., Medzhidova M. K. Nonspecific vaginitis: etiology, pathogenesis, clinic, diagnosis, modern principles of treatment. Akusherstvo i ginekologiya. 2011; 7-2: 92-96. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Васильев М. М., Наволоцкая Т. И., Смирнова А. А., Фриго Н. В., Ротанов С. В., Сидорович С. Ю. Применение джозамицина (вильпрафена) у женщин с хламидийной инфекцией нижних и верхних отделов мочеполового тракта. Вестник дерматологии и венерологии. 2005; 3: 78-80.</mixed-citation><mixed-citation xml:lang="en">Vasilev M. M., Navolotskaya T. I., Smirnova A. A., Frigo N. V., Rotanov S. V., Sidorovich S. Yu. The use of josamycin (vilprafen) in women with chlamydial infection of the lower and upper parts of the urogenital tract. Vestnik dermatologii i venerologii. 2005; 3: 78-80. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Мирская Ю. И., Рудакова Е. Б., Шакира И. А., Цыганкова О. Ю. Роль цервицитов в акушерско-гинекологической патологии. Лечащий Врач. LECHASCHI VRACH, VOL. 28, № 6, 2025, https://journal.lvrach.ru/</mixed-citation><mixed-citation xml:lang="en">Mirskaya Yu. I., Rudakova E. B., Shakira I. A., Tsygankova O. Yu. Role of cervicitis in obstetric and gynecologic pathology. Lechaschi Vrach. 2009; 10: 63-66. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Keskin-Arslan E., Erol H., Uysal N., Karadas B., Temiz T., Kaplan Y. C. Pregnancy outcomes following maternal macrolide use: a systematic review and meta-analysis. Reprod Toxicol. 2023; 115: 124-146. DOI: 10.1016/j.reprotox.2022.12.003. PubMed.</mixed-citation><mixed-citation xml:lang="en">Keskin-Arslan E., Erol H., Uysal N., Karadas B., Temiz T., Kaplan Y. C. Pregnancy outcomes following maternal macrolide use: a systematic review and meta-analysis. Reprod Toxicol. 2023; 115: 124-146. DOI: 10.1016/j.reprotox.2022.12.003. PubMed.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Blotière P.-O., Weill A., Dalichampt M., Billionnet C., Mezzarobba M., Raguideau F., et al. Development of an algorithm to identify pregnancy episodes and related outcomes in health care claims databases: an application to antiepileptic drug use in 4.9 million pregnant women in France. Pharmacoepidemiol Drug Saf. 2018; 27 (7): 763-770. DOI 10.1002/pds.4556. PMC – PubMed.</mixed-citation><mixed-citation xml:lang="en">Blotière P.-O., Weill A., Dalichampt M., Billionnet C., Mezzarobba M., Raguideau F., et al. Development of an algorithm to identify pregnancy episodes and related outcomes in health care claims databases: an application to antiepileptic drug use in 4.9 million pregnant women in France. Pharmacoepidemiol Drug Saf. 2018; 27 (7): 763-770. DOI 10.1002/pds.4556. PMC – PubMed.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Blotière P.-O., Raguideau F., Weill A., Elefant E., Perthus I., Goulet V., et al. Risks of 23 specific malformations associated with prenatal exposure to 10 antiepileptic drugs. Neurology. 2019; 93 (2): 167-80. DOI: 10.1212/WNL.0000000000007696. PMC – PubMed.</mixed-citation><mixed-citation xml:lang="en">Blotière P.-O., Raguideau F., Weill A., Elefant E., Perthus I., Goulet V., et al. Risks of 23 specific malformations associated with prenatal exposure to 10 antiepileptic drugs. Neurology. 2019; 93 (2): 167-80. DOI: 10.1212/WNL.0000000000007696. PMC – PubMed.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Lassalle M., Zureik M., Dray-Spira R. Proton pump inhibitor use and risk of serious infections in young children. JAMA Pediatr. 2023; 177 (10): 1028-1038. DOI 10.1001/jamapediatrics.2023.2900. PMC – PubMed.</mixed-citation><mixed-citation xml:lang="en">Lassalle M., Zureik M., Dray-Spira R. Proton pump inhibitor use and risk of serious infections in young children. JAMA Pediatr. 2023; 177 (10): 1028-1038. DOI 10.1001/jamapediatrics.2023.2900. PMC – PubMed.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Минкевич К. В., Зайцева А. А. Применение макролида нового поколения для лечения генитального хламидиоза у женщин. Акушерство и гинекология. 2001; 8: 14-18.</mixed-citation><mixed-citation xml:lang="en">Minkevich K. V., Zaitseva A. A. Application of new generation macrolide for treatment of genital chlamydia in women. Akusherstvo i ginekologiya. 2001; 8: 14-18. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">EUROCAT Guide 1.4 and Reference Documents. European Surveillance of Congenital Anomalies; 2018. Available from: https://eu-rd-platform.jrc.ec.europa.eu/sites/default/files/Full_Guide_1.</mixed-citation><mixed-citation xml:lang="en">EUROCAT Guide 1.4 and Reference Documents. European Surveillance of Congenital Anomalies; 2018. Available from: https://eu-rd-platform.jrc.ec.europa.eu/sites/default/files/Full_Guide_1.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Desai R. J., Rothman K. J., Bateman B. T., Hernandez-Diaz S., Huybrechts K. F. A propensity-score-based fine stratification approach for confounding adjustment when exposure is infrequent. Epidemiology. 2017. Р. 249-257. Available from: https://www.ncbi.nlm.nih.gov/pubmed/27922533. PMC – PubMed.</mixed-citation><mixed-citation xml:lang="en">Desai R. J., Rothman K. J., Bateman B. T., Hernandez-Diaz S., Huybrechts K. F. A propensity-score-based fine stratification approach for confounding adjustment when exposure is infrequent. Epidemiology. 2017. Р. 249-257. Available from: https://www.ncbi.nlm.nih.gov/pubmed/27922533. PMC – PubMed.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Таточенко В. К. Джозамицин в педиатрической практике. Педиатрия. 2011; 5 (90): 124-128. Tatochenko V. К. Josamycin in pediatric practice. Pediatriya. 2011; 5 (90): 124-128. (In Russ.)</mixed-citation><mixed-citation xml:lang="en">Tatochenko V. К. Josamycin in pediatric practice. Pediatriya. 2011; 5 (90): 124-128. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Савичева А. М., Шипицина Е. В., Селимян Н. К. Вильпрафен (джозамицин) в терапии урогенитальной хламидийной инфекции. Вестник дерматологии и венерологии. 2004; 2: 62-65.</mixed-citation><mixed-citation xml:lang="en">Savicheva A.M., Shipitsina E. V., Selimyan N. K. Vilprafen (josamycin) in the therapy of urogenital chlamydial infection. Vestnik dermatologii i venerologii. 2004; 2: 62-65. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Кисина В. И., Ковалык В. П., Колиева Г. Л. Критерии выбора рекомендованных и альтернативных методов лечения урогенитальных инфекций. Трудный пациент. 2005; 2.</mixed-citation><mixed-citation xml:lang="en">Kisina V. I., Kovalyk V. P., Kolieva G. L. Criteria for the choice of recommended and alternative methods of treatment of urogenital infections. Trudnyi patsient. 2005; 2. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Малова И. О. Вильпрафен (джозамицин) в лечении хламидийной и смешанных инфекций урогенитального тракта у девочек младшего возраста. Российский вестник перинатологии и педиатрии. 2001; 4.</mixed-citation><mixed-citation xml:lang="en">Malova I. O. Vilprafen (jozamycin) in the treatment of chlamydial and mixed infections of the urogenital tract in young girls. Rossiiskii vestnik perinatologii i pediatrii. 2001; 4. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Инструкция по медицинскому применению препарата Джозафен.</mixed-citation><mixed-citation xml:lang="en">.Instructions for the medical use of the Dzhozafen drug (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Проспективное, открытое, рандомизированное, полное репликативное, четырехпериодное, с двумя последовательностями, перекрестное исследование по изучению сравнительной фармакокинетики и биоэквивалентности препаратов Джозафен® (МНН: джозамицин), таблетки, покрытые пленочной оболочкой, 500 мг (производства ОАО «Фармстандарт-Лексредства», Россия) и Вильпрафен® (МНН: джозамицин) таблетки, покрытые пленочной оболочкой, 500 мг (производства «АстелласФармаЮроп Б.В.», Нидерланды) у здоровых добровольцев.</mixed-citation><mixed-citation xml:lang="en">A prospective, open-label, randomized, full replicative, four-period, two-sequence, crossover study of the comparative pharmacokinetics and bioequivalence of Dzhozafen® (INN: josamycin), film-coated tablets, 500 mg (manufactured by Pharmstandard-Leksredstva OJSC, Russia) and Wilprafen® (INN: josamycin) film-coated tablets, 500 mg (manufactured by Astellas Pharma Europe B. V., Netherlands) in healthy volunteers. (In Russ.)</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
